TVGN

Tevogen Bio Holdings Inc. (TVGN) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell platform) for infectious diseases, cancers, and neurological disorders. The company completed a reverse recapitalization (Business Combination) with Semper Paratus Acquisition Corporation on February 14, 2024. As of June 30, 2024, the company had no product revenue and remains in the development stage.

Key Financial Metrics

Debt and Liquidity: The company holds a $36.0 million unsecured line of credit (Loan Agreement) allowing draws of up to $1.0 million per month. As of June 30, 2024, no principal had been drawn under this facility, though $1.0 million was drawn subsequently in July and August 2024. The company reported $1.14 million in cash on hand.

Material Changes vs. Prior Period

• Net Income Volatility: The company reported a net loss of $9.66 million for Q2 2024, contrasting with a net income of $1.60 million for the six months ended June 30, 2024. The YTD income was driven by a $48.5 million non-cash gain from the change in fair value of convertible promissory notes prior to their conversion in the Merger, partially offset by $38.1 million in operating expenses and $7.5 million in merger transaction costs.
• Expense Surge: Operating expenses increased significantly to $38.12 million for the six months ended June 30, 2024, compared to $4.51 million in the prior year period. This increase is primarily attributed to $30.5 million in non-cash stock-based compensation expense recognized upon the satisfaction of liquidity conditions during the Merger.
• Balance Sheet Restructuring: Total liabilities decreased from $99.9 million (Dec 31, 2023) to $10.9 million (June 30, 2024). This reduction was due to the conversion of $94.9 million in convertible promissory notes into common stock during the Merger.
• Stock-Based Compensation: $30.5 million of stock-based compensation was recognized in the first half of 2024, compared to zero in the same period in 2023.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management believes current cash ($1.14 million) combined with the $36.0 million Loan Agreement provides sufficient resources to operate for at least the next 12 months. The company does not plan to initiate new clinical trials until additional funding is secured.
• Unusual Items:
  • Merger Transaction Costs: $7.5 million in costs were expensed in the first half of 2024.
  • Stock-Based Compensation: A significant portion of operating expenses ($30.5 million YTD) was non-cash stock-based compensation related to the Merger and a special RSU award to the CEO.
  • Derivative Liabilities: The company recorded liabilities for written call options associated with the Loan Agreement ($213,214) and private warrants ($22,185).
• Risks and Contingencies:
  • Nasdaq Compliance: The company received notice on June 14, 2024, of non-compliance with Nasdaq's $1.00 minimum bid price requirement. It has 180 days to regain compliance or risk delisting.
  • Going Concern: While the Loan Agreement provides a runway, the company has a history of losses and will require additional capital to advance clinical trials and commercialization.
  • Internal Controls: Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.

Investor Verification Checklist

• Verify Liquidity Runway: Confirm the status of the $36.0 million Loan Agreement draws and the remaining $3.0 million deposit for the Series A-1 Preferred Stock issuance.
• Nasdaq Compliance Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
• Stock-Based Compensation Impact: Review the vesting schedule and future expense recognition for the $87.3 million CEO RSU award and other performance-based awards.
• Debt Covenants: Examine the terms of the Loan Agreement, specifically the interest payment in stock and the contingent purchase options (PIPE) that could trigger significant dilution if the stock price reaches $10.00.
• Internal Control Remediation: Assess the plan to address the material weaknesses in internal controls over financial reporting.